BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27713150)

  • 21. Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.
    Chen Z; Wang L; Yao D; Yang T; Cao WM; Dou J; Pang JC; Guan S; Zhang H; Yu Y; Zhao Y; Wang Y; Xu X; Shi Y; Patel R; Zhang H; Vasudevan SA; Liu S; Yang J; Nuchtern JG
    Sci Rep; 2016 Dec; 6():38011. PubMed ID: 27991505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells.
    Czaplinski S; Abhari BA; Torkov A; Seggewiß D; Hugle M; Fulda S
    Oncotarget; 2015 Dec; 6(39):41522-34. PubMed ID: 26575016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
    Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
    Qian G; Yao W; Zhang S; Bajpai R; Hall WD; Shanmugam M; Lonial S; Sun SY
    Cancer Lett; 2018 Oct; 435():44-54. PubMed ID: 30059709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
    Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
    Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
    Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
    Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
    Wang M; Liang L; Lu J; Yu Y; Zhao Y; Shi Z; Li H; Xu X; Yan Y; Niu Y; Liu Z; Shen L; Zhang H
    Thorac Cancer; 2019 Apr; 10(4):918-929. PubMed ID: 30883017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.
    Cheng J; Fan YH; Xu X; Zhang H; Dou J; Tang Y; Zhong X; Rojas Y; Yu Y; Zhao Y; Vasudevan SA; Zhang H; Nuchtern JG; Kim ES; Chen X; Lu F; Yang J
    Cell Death Dis; 2014 Feb; 5(2):e1079. PubMed ID: 24556694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
    Deshmukh RR; Kim S; Elghoul Y; Dou QP
    J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoptosis induced by trimethyltin chloride in human neuroblastoma cells SY5Y is regulated by a balance and cross-talk between NF-κB and MAPKs signaling pathways.
    Qing Y; Liang Y; Du Q; Fan P; Xu H; Xu Y; Shi N
    Arch Toxicol; 2013 Jul; 87(7):1273-85. PubMed ID: 23423712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
    Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
    Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
    Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
    Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear factor-kappa B and apoptosis inducing factor activation by doxorubicin analog WP744 in SH-SY5Y neuroblastoma cells.
    Wu J; Harris NL; Inge TH
    J Surg Res; 2004 Dec; 122(2):231-9. PubMed ID: 15555623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib.
    Thakur S; Ruan Y; Jayanthan A; Boklan J; Narendran A
    Curr Cancer Drug Targets; 2021; 21(9):804-811. PubMed ID: 33949932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
    Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
    Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
    PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
    Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.